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Conclusions: Coronary implantation of BES or SES is associated with similar event rates
at 12-month follow-up in patients with, and without, diabetes.
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Background: The aim of this study is to compare the safety and efficacy of Sirolimus
(SES), Paclitaxel (PES), EPC capture (ECS), Zotarolimus (ZES-R/ Endeavor Resolute),
BiolimusA9 (BES) and Everolimus-eluting stent (EES) on the outcome of percutaneous
coronary intervention in patients with diabetes mellitus (DM).
Methods: A prospective analysis of 2972 patients with DM (808 SES, 720 PES,
299 ECS, 404 ZES-R, 320 BES, 421 EES) in six high volume Asian centers after
successful stenting was performed. The study endpoints were 30 days major
adverse cardiac events (MACE) and 12, 24 and 36 months target lesion
revascularization (TLR) and MACE.
Results: See table for clinical results.
Conclusions: The use of drug-eluting stents in patient with DM was safe with low acute
complication. Patients treated with BES and EES showed lesser rate of restenosis
compared with ECS.
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Background: The aim of this study is to compare the safety and efficacy of Sirolimus
(SES), Paclitaxel (PES), Zotarolimus (ZES-R/ Endeavor Resolute), BiolimusA9 (BES),
EPC capture (ECS) and Everolimus-eluting stent (EES) on the outcome of treatment of
small coronary artery disease with diabetes mellitus (DM).
Methods: A prospective analysis of 1670 patients with diabetic small coronary artery
stenosis (420 SES, 360 PES, 249 ZES, 200 BES, 153 ECS, 288 EES) in six high volume
Asian centers after successful stent implantation was performed. The study endpoints
were major adverse events (MACE) at 30 days, 12 months restenosis rate and target lesion
revascularization (TLR) at 12 months.
Results: See table for clinical results.
Conclusions: The use of drug-eluting stents in patients with diabetic small coronary
artery stenosis was safe and feasible. Patients treated with BES and EES showed lesser
rate of restenosis compared with ECS.
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Background: The aim of this study is to compare the safety and efficacy of
Sirolimus (SES), Paclitaxel (PES), Zotarolimus (ZES-R/ Endeavor Resolute),
BiolimusA9 (BES), EPC capture (ECS) and Everolimus-eluting stent (EES) on the
outcome of stenting in patients with diabetic very long coronary lesion (VLL)
(lesion length 40 mm).
Methods: A prospective analysis of 1317 patients with diabetic VLL (328 SES, 280 PES,
189 ZES-R, 190 BES, 143 ECS, 187 EES) was performed. The study endpoints were
major adverse cardiac events (MACE) at 12 months, restenosis rate and target lesion
revascularization (TLR) at 12 months.
Results: See table for clinical results.
Conclusions: (1) The use of drug-eluting stents in patients with diabetic VLL seems to
be favorable in terms of in-hospital clinical outcome and long-term results. (2) Patients
treated with BES and EES showed lesser restenosis rate and TLR compared with PES and
ECS.
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